EPIC Translation Repository

These translations and validations of EPIC were not created by our team at the University of Michigan. We are simply providing them as a resource for those who might be interested in using them. Therefore, if you would like more information on any of these translations and validations, please reach out to the primary authors listed below.

Translation	Language	Dialect/ Country	Version of EPIC	Primary Author	Translation Group	Validation Citation	Validation Methods
<u>Link</u>	Chinese	Traditional Chinese	EPIC 26	Wendy W. T. Lam	The University of Hong Kong Pok Fu Lam, Hong Kong	1	Forward translation, review, back translation, amendments, repeated until English versions had matched meanings
<u>Link</u>	Chinese	Cantonese	EPIC 50	Tsz Kin Lee	Department of Radiation Oncology, Abbotsford Cancer Centre, British Columbia Cancer Agency British Columbia, Canada	<u>2</u>	2 forward translations, combined to 1, back translation
<u>Link</u>	Chinese	Simplified Chinese	EPIC 26	Harriet Mead	ICON Language Services Oxfordshire, United Kingdom	<u>15</u> , <u>16</u>	Concept elaboration, dual forward translation, dual back translation, adapt, cognitive debriefing, proofreading and final verification
<u>Link</u>	Dutch	Netherlands	EPIC 50	Julia vanTol- Geerdink	Department of Radiation Oncology/Urology/Public Health, Radboud University Medical Centre Nijmegen, The Netherlands	<u>3</u> , <u>4</u>	Forward translation, discussion until consensus
<u>Link</u>	Filipino	Philippines	EPIC 50	Warren Bacorro	University of Santo Tomas, Venavides Cancer Institute, Manila, Philippines		Forward and back-translation, expert panel review, pilot testing and focus group discussion, and revision
Link	French	Canada	EPIC 26	Éric Vigneault	CHU de Québec-Université Laval Research Centre Quebec City, QC, Canada	<u>5</u>	Translated EPIC 26 to French, 2 translators assessed and suggested alternative wording, translated EPIC 50 to French, one of two versions (EPIC 26/50) or combination of each item was kept, repeated process but with Canadian French translators
<u>Link</u>	French	Canada	EPIC 50	Éric Vigneault	CHU de Québec-Université Laval Research Centre Quebec City, QC, Canada	<u>5</u>	Translated EPIC 26 to French, 2 translators assessed and suggested alternative wording, translated EPIC 50 to French, one of two versions (EPIC 26/50) or combination of each item was kept, repeated process but with Canadian French translators

<u>Link</u>	French	Belgium	EPIC 26	MAPI Research Trust	MAPI Research Trust	<u>6</u>	2 forward translation or review/adaptation, back translation, 5 cognitive interviews, international harmonisation
<u>Link</u>	French	France	EPIC 26	MAPI Research Trust	MAPI Research Trust	<u>7</u>	2 forward translation or review/adaptation, back translation, 5 cognitive interviews, international harmonisation
<u>Link</u>	German	Germany	EPIC 26	Nora T. Sibert	German Cancer Society Berlin, Germany	<u>8</u>	Translation and retranslation, inaccuracies discussed, consensus reached, revised by doctors, tested by patients
<u>Link</u>	German	Germany, Austria, Switzerland	EPIC 50	Martin H. Umbehr	University of Zurich Zurich, Switzerland	9	Forward translations, pilot testing, back translation, pilot testing, validation process
Link	Hebrew	Israel	EPIC 26	Symon Zvi	Department of Radiation Oncology, Sheba Medical Center Israel	<u>17</u>	2 forward translation, review, back translation, amendments, repeated until English versions had matched meanings
<u>Link</u>	Korean	Korea	EPIC 50	Sung Won Lee	Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul, Korea	<u>10</u>	2 forward translations, combined to one, back translation, amendments
<u>Link</u>	Norwegian	Norway	EPIC 26	Sophie D. Fosså	Oslo University Hospital Oslo, Norway	14	Translated, tested & corrected, back translated, compared with English US version
<u>Link</u>	Spanish	US	EPIC 26	Donna L. Berry	The Phyllis F. Cantor Center, Dana- Farber Cancer Institute Boston, MA, USA	<u>11</u>	Forward and backtranslation by 3 translators (2 Mexican, 1 Puerto Rican), review by bilingual study staff, discussion with translators staff and PI
<u>Link</u>	Spanish	Spain	EPIC 26	Montserrat Ferrer Forés	Unidad de Investigación en Servicios Sanitarios, IMIM-Hospital del Mar <i>Barcelona, España.</i>	<u>12</u>	Translation and back-translation
Link	Spanish	Spain	EPIC 50	Montserrat Ferrer Forés	Unidad de Investigación en Servicios Sanitarios, IMIM-Hospital del Mar Barcelona, España.	<u>12</u>	Translation and back-translation
<u>Link</u>	Spanish	Spain	EPIC-CP	Jae Lee	University of Michigan Ann Arbor, MI	<u>13</u>	Translation and back-translation
<u>Link</u>	Turkish	Turkey	EPIC-CP	Ayşe GÖKTAŞ	Ege University Nursing Faculty Izmir, Turkey		

Citations

- 1. Lam WWT, Tse MA, Ng CNL, Chung EKM, Fielding R. Psychometric Assessment of the Chinese Version of the Abbreviated Expanded Prostate Cancer Index Composite (EPIC-26) and the Clinical Practice Version (EPIC-CP) in Chinese Men With Prostate Cancer. Journal of pain and symptom management. 2017;53(6):1085-1090.
- 2. Lee TK, Poon DMC, Ng ACF, et al. Cultural adaptation and validation of the Chinese version of the expanded prostate cancer index composite. Asia-Pacific journal of clinical oncology. 2018;14 Suppl 1:10-15.
- Venderbos LDF, Aluwini S, Roobol MJ, et al. Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer. Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation. 2017;26(6):1635-1645.
- 4. van Tol-Geerdink JJ, Leer JW, van Oort IM, et al. Quality of life after prostate cancer treatments in patients comparable at baseline. British journal of cancer. 2013;108(9):1784-1789.
- 5. Vigneault E, Savard J, Savard MH, et al. Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French-Canadian population. Canadian Urological Association journal = Journal de l'Association des urologues du Canada. 2017;11(12):404-410.
- 6. French (Belgium) MAPI Research Trust Documentation.
- 7. French (France) MAPI Research Trust Documentation.
- 8. Sibert NT, Dieng S, Oesterle A, et al. Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancer. *World journal of urology*. 2019:10.1007/s00345-00019-02949-00347.
- 9. Umbehr MH, Bachmann LM, Poyet C, et al. The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation. Health and quality of life outcomes. 2018;16(1):36.
- 10. Chung KJ, Kim JJ, Lim SH, Kim TH, Han DH, Lee SW. Development and validation of the korean version of expanded prostate cancer index composite: questionnaire assessing health-related quality of life after prostate cancer treatment. Korean J Urol. 2010;51(9):601-612.
- 11. Berry DL, Halpenny B, Bosco JLF, Bruyere J, Jr., Sanda MG. Usability evaluation and adaptation of the e-health Personal Patient Profile-Prostate decision aid for Spanish-speaking Latino men. BMC medical informatics and decision making. 2015;15:56.
- 12. Ferrer M, Garin O, Pera J, et al. Evaluation of the quality of life of patients with localized prostate cancer: validation of the Spanish version of the EPIC. Med Clin (Barc). 2009;132(4):128-135.
- 13. Lee JY, Daignault-Newton S, Heath G, et al. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. Int J Radiat Oncol Biol Phys. 2016;96(4):770-777.
- 14. Fosså SD, Storås AH, Steinsvik EA, et al. Psychometric testing of the Norwegian version of the Expanded Prostate Cancer Index Composite 26-item version (EPIC-26). Scand J Urol. 2016;50(4):280-285.
- 15. ICON Clinical Research (UK) Limited. Translation and Linguistic Validation Report: EPIC-26.
- 16. ICON Language Services. Methodology Certification Letter.
- 17. Kushner T, Gofrit ON, Elkayam R, Paluch-Shimon S, Lawrence YR, Weiss L, Symon Z. Impact of androgen deprivation therapy on sexual and hormonal function in patients receiving radiation therapy for prostate cancer. Isr Med Assoc J. 2016;18(1):49-53.